title: Human urotensin II as a link between hypertension and coronary artery disease.
abstract: Hypertension is a well-known risk factor for atherosclerosis, but the molecular mechanisms that link elevated blood pressure to the progression of atherosclerosis remain unclear. Human urotensin II (U-II), the most potent endogenous vasoconstrictor peptide identified to date, and its receptor (UT receptor) are involved in the etiology of essential hypertension. In patients with essential hypertension, U-II infused into the forearm brachial artery has been shown to induce vasoconstriction. Recent studies have demonstrated elevated plasma U-II concentrations in patients with essential hypertension, diabetes mellitus, atherosclerosis, and coronary artery disease. U-II is expressed in endothelial cells, macrophages, macrophage-derived foam cells, and myointimal and medial vascular smooth muscle cells (VSMCs) of atherosclerotic human coronary arteries. UT receptors are present in VSMCs of human coronary arteries, the thoracic aorta and cardiac myocytes. Lymphocytes are the most active producers of U-II, whereas monocytes and macrophages are the major cell types expressing UT receptors, with relatively little receptor expression in foam cells, lymphocytes, and platelets. U-II accelerates foam cell formation by up-regulation of acyl-coenzyme A:cholesterol acyltransferase-1 in human monocyte-derived macrophages. In human endothelial cells, U-II promotes cell proliferation and up-regulates type 1 collagen expression. U-II also activates nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and plasminogen activator inhibitor-1 in human VSMCs, and stimulates VSMC proliferation with synergistic effects observed when combined with oxidized low-density lipoprotein, lysophosphatidylcholine, reactive oxygen species or serotonin. These findings suggest that U-II plays key roles in accelerating the development of atherosclerosis, thereby leading to coronary artery disease.
authors.affiliation: Department of Biochemistry, Showa University School of Medicine, Tokyo, Japan. watanabemd@med.showa-u.ac.jp
authors.forename: Takuya
authors.initials: T
authors.lastname: Watanabe
authors.forename: Tomoko
authors.initials: T
authors.lastname: Kanome
authors.forename: Akira
authors.initials: A
authors.lastname: Miyazaki
authors.forename: Takashi
authors.initials: T
authors.lastname: Katagiri
mesh_terms: D000818:Animals; D050197:Atherosclerosis / Q000097:blood / Q000209:etiology / Q000503:physiopathology*; D001792:Blood Platelets / Q000473:pathology; D049109:Cell Proliferation / Q000187:drug effects; D003324:Coronary Artery Disease / Q000097:blood / Q000209:etiology* / Q000503:physiopathology*; D023903:Coronary Restenosis / Q000209:etiology / Q000503:physiopathology; D004730:Endothelium, Vascular / Q000473:pathology; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology*; D043562:Receptors, G-Protein-Coupled / Q000037:antagonists & inhibitors / Q000502:physiology; D014579:Urotensins / Q000097:blood / Q000502:physiology*; D014661:Vasoconstriction / Q000187:drug effects / Q000502:physiology
chemical_list: D043562:Receptors, G-Protein-Coupled; C121697:UTS2R protein, human; D014579:Urotensins; C029677:urotensin II